Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
PROVECTUS PHARMACEUTICALS logo — Developing advanced therapies to target and destroy the dead...

PROVECTUS PHARMACEUTICALS

Developing advanced therapies to target and destroy the deadliest cancers – melanoma, liver, and breast – while eliminating side effects

Founded 1978 Post Ipo Equity Total: $10.59M Biotechnology, Pharmaceutical

General Information

Company Name PROVECTUS PHARMACEUTICALS
Founded Year 1978
Industries Biotechnology, Pharmaceutical
Funding Stage Post Ipo Equity
Social

Get notified when PROVECTUS PHARMACEUTICALS moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About PROVECTUS PHARMACEUTICALS

Provectus Pharmaceuticals is a biotechnology and pharmaceutical company that is dedicated to developing advanced therapies to target and destroy the deadliest cancers, including melanoma, liver, and breast cancers, while also placing a significant emphasis on reducing side effects. Established in 1978 as "SPM Group, Inc.," the company underwent a transition in 1992 to refocus its efforts on pursuing acquisitions. With a last investment of $3.37M in post-IPO equity that took place on April 17, 2014, Provectus Pharmaceuticals continues to attract attention and support within the industry. The company's innovative approach and strategic positioning within the biotechnology and pharmaceutical industries make it a compelling prospect for investors seeking to contribute to the advancement of cancer treatment.

Taxonomy: Cancer Therapy, Medical Research, Drug Development, Advanced Therapies, Melanoma, Liver Cancer, Breast Cancer, Pharmaceutical Company, Acquisitions, Development-Stage Company, Healthcare Innovation

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Equity •••••• - 17 Apr 2014
Post-IPO Equity •••••• - 07 Aug 2009
Post-IPO Equity •••••• - 30 Jun 2009

PROVECTUS PHARMACEUTICALS Alternatives & Competitors

PROVECTUS PHARMACEUTICALS vs
Aragon Pharmaceuticals
Aragon Pharmaceuticals

Pioneering breakthrough treatments for hormone-resistant prostate and breast cancers.

Series D
Biotechnology, Health Care
PROVECTUS PHARMACEUTICALS vs
Semafore Pharmaceuticals
Semafore Pharmaceuticals

Pioneering the future of cancer treatment with innovative PI3K inhibitors.

Series B
Biotechnology, Health Care
PROVECTUS PHARMACEUTICALS vs
Teon Therapeutics Inc.
Teon Therapeutics Inc. United States

Teon is a clinical company targeting metabolic signaling pathways and pioneering the development of...

Series A
7 employees
Biopharma, Biotechnology

FAQ About PROVECTUS PHARMACEUTICALS

Developing advanced therapies to target and destroy the deadliest cancers – melanoma, liver, and breast – while eliminating side effects
PROVECTUS PHARMACEUTICALS was founded in 1978.
PROVECTUS PHARMACEUTICALS operates in the following industries: Biotechnology, Pharmaceutical.
PROVECTUS PHARMACEUTICALS has completed 3 funding rounds, raising a total of $10.59M. The latest funding stage is Post Ipo Equity.
Top alternatives and competitors to PROVECTUS PHARMACEUTICALS include Aragon Pharmaceuticals, Semafore Pharmaceuticals, Teon Therapeutics Inc., Remicalm, MILAGEN, INC.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
PROVECTUS PHARMACEUTICALS and Aragon Pharmaceuticals are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors PROVECTUS PHARMACEUTICALS and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy